We use sequencing technologies to identify novel targets and biomarkers and can analyze the mode of action of development compounds at unprecedented resolutions.
Our NGS platform services include:
Read more: Functional Genomics
Proteomics techniques can measure the expression levels of thousands of proteins simultaneously, allowing for the quick and efficient identification of potential biomarkers.
We offer quantitative proteomic analysis of complex biological samples from various sources, such as tissue, cell lysates, and body fluids. Available workflows include isobaric and metabolic labeling approaches, as well as label-free measurements, phospho-proteomics, protein interaction profiling, and targeted assays. Our in-depth experience in proteomics is complemented by comprehensive statistics and bioinformatics services. This allows us to not only analyze and interpret complex proteomic data, but also put it into the context of specific research questions, providing a deeper understanding of underlying biological mechanisms.
Immunoprofiling is an integral part of drug discovery. It plays a critical role in identifying and validating drug targets, optimizing drug candidates, and predicting clinical efficacy and safety. We use immunoprofiling to gain a better understanding of the mechanisms of action of potential drugs and identify biomarkers that can be used to select patient populations that are most likely to benefit from novel immunotherapies.
We offer comprehensive profiling using panels for oncology, immunology/inflammation (cytokines/chemokines), and other indications using the platforms Meso Scale (MESO SECTOR S 600, MESO QuickPlex SQ 120), homogeneous time-resolved fluorescence (HTRF), and enzyme-linked immunosorbent assay (ELISA). Our human peripheral blood mononuclear cell (PMBC) inflammation platform includes various disease-specific readouts.
Read more: Primary cell-based assays
Multicolor flow cytometry is a valuable tool in drug discovery for identifying new drug targets, screening potential drug candidates, and analyzing the effects of drugs on specific cell populations.
We offer comprehensive panels for Immuno-profiling, and also assays for all major immune cell populations, established and validated for mouse and human.
Immunohistochemistry (IHC) is a powerful tool that can be used for identification and validation of novel drug targets, characterization of disease pathology, evaluation of drug efficacy in preclinical models and clinical trials, and patient selection based on their biomarker profiles, allowing for more targeted and personalized treatment approaches.
We offer spatial profiling using multicolor immunofluorescence to identify different types of immune cells that infiltrate a tumor, such as T cells, B cells, natural killer cells, and myeloid-derived suppressor cells. We have established multiple markers for IF and IHC.
Read more: Immunohistochemistry
We offer RNA in situ hybridization using RNAscope™ technology, enabling in situ detection and quantification of single RNA molecules, providing spatial gene expression results. We also use RNA in situ hybridization to independently cross-validate antibodies for IHC or as an alternative assay in case no suitable antibody for IHC can be identified. We offer single and dual fluorescent and chromogenic stainings, as well dual IHC-RNAscope™ duplex staining for the analysis of preclinical and clinical samples.
Quantitative real-time polymerase chain reaction (qRT-PCR) is a highly sensitive and specific technique used to measure gene expression levels in biological samples. It is rapid and cost-effective, which makes it an attractive option for high-throughput screening of biomarker responses to potential drug candidates. We offer qPCR profiling of preclinical and clinical samples in a 384-well format.
We offer protein expression profiling of preclinical and clinical samples using Simple Western technology (Simple Western Jess and Peggy Sue). Simple Western automates the protein separation and immunodetection of traditional Western blotting, eliminating many error-prone steps.
In addition to size-based separation, we also offer Simple Western capillary isoelectric focusing (cIEF) for the characterization of post-translational protein modifications.
Proximity ligation assays can be used to study endogenous protein–protein interactions in situ. We offer proximity ligation assays and assay development for your targets.
Blood-based biomarker assays are a critical component of drug discovery and development, providing valuable information about the safety and efficacy of potential drug candidates in easily obtainable samples.